Licensing & Business Development

ReGenX views licensing and business development as an important part of its mission to enable the development of a pipeline of novel AAV vector based therapeutics. We believe there is value in forming alliances with leading research institutions to further develop our capabilities in the applications for delivering genetic materials directly to specific sites of disease through various molecular therapeutic methods including, gene therapy, gene silencing (i.e. RNAi) or stem cells.

We are interested in creating partnerships with biotechnology companies that complement our expertise and novel AAV vector technology platform with knowledge of specific molecular pathways and targets of disease for the development of therapeutics. We will grant licenses to biotechnology companies for the development and commercialization of novel AAV vector based therapeutics for specified molecular targets or to biotechnology companies that wish to use our AAV vector technologies for basic research and development.

If you have interest in discussing licensing or partnering opportunities with ReGenX,
please contact Business Development.